Objective and subjective measures of dalfampridine efficacy in clinical practice
{{output}}
Background: Multiple sclerosis affects mobility in over 80% of patients. Dalfampridine is the only approved treatment for walking impairment in multiple sclerosis. We assessed dalfampridine utilization in our practice and investi... ...
